



Citi Pharma Limited

April 29, 2026

General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building, Stock Exchange Road,
Karachi – 74000, Pakistan

Subject: Financial Results for the Quarter ended March 31, 2026 (Un-audited)

Dear Sir,

We have to inform you that the Board of Directors of Citi Pharma Limited in their meeting held on Wednesday, April 29, 2026, at 02:30 p.m. at its Head Office located at 588 Block Q, Johar Town, Lahore, recommended the following: -

- | | | |
|--|---|-----|
| 1) Cash Dividend | : | Nil |
| 2) Bonus Shares | : | Nil |
| 3) Right Shares | : | Nil |
| 4) Any Other Entitlement | : | Nil |
| 5) Any Other Price-Sensitive Information | : | Nil |

The Financial Results of the Company are attached.

The Quarterly Report of the Company for the period ended March 31, 2026, will be transmitted through PUCARS separately.

Yours truly,

M. Rasheed Alam
Company Secretary



Cc: The Executive Director / HOD
Offsite-II Department
Supervision Division
Securities & Exchange Commission of Pakistan
63 – NIC Building, Jinnah Avenue
Blue Area, Islamabad.



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT MARCH 31, 2026

	March 31, 2026 (Un-audited)	June 30, 2025 (Audited)
Note	-----Rupees-----	
EQUITY AND LIABILITIES		
SHARE CAPITAL AND RESERVES		
Authorized Capital:		
300,000,000 Ordinary shares of Rs. 10/ each	3,000,000,000	3,000,000,000
Share Capital and Reserves:		
228,461,200 (June 2025: 228,461,200) Ordinary Shares Of Rs. 10/ Each	2,284,612,000	2,284,612,000
Share Premium	1,391,532,000	1,391,532,000
Revenue Reserves-Unappropriated Profits	1,890,643,407	1,806,817,381
Revaluation Surplus On Land	5,384,617,300	5,384,617,300
	10,951,404,707	10,867,578,681
NON-CURRENT LIABILITIES		
Long Term Financing - Secured	30,714,500	-
Deferred Liabilities	208,734,107	201,763,862
Lease Liabilities	53,207,092	64,864,123
	292,655,700	266,627,986
CURRENT LIABILITIES		
Trade and Other Payables	3,598,797,887	3,858,531,251
Due to Related Parties	-	5,686,383
Short Term Borrowings-Secured	3,419,760,128	2,863,211,696
Current Portion of Long Term Liabilities-Secured	62,186,419	15,802,536
Dividend Payable	2,502,154	4,065,868
Accrued Mark Up	86,081,710	38,268,523
Provision For Taxation	464,125,013	519,677,557
	7,633,453,313	7,305,243,814
Contingencies and Commitments	-	-
TOTAL EQUITY AND LIABILITIES	18,877,513,719	18,439,450,481
ASSETS		
NON CURRENT ASSETS		
Property, Plant and Equipment	8,624,089,332	8,687,898,852
Long Term Security Deposits	27,793,117	25,443,117
Long Term Advance	254,540,900	254,540,900
	8,906,423,349	8,967,882,869
CURRENT ASSETS		
Stock in Trade	4,406,558,998	3,929,701,530
Trade Debts- Unsecured	4,217,486,908	3,078,215,648
Advances Deposits, Prepayments and Other Receivables	1,022,856,402	903,708,936
Short Term Investments	3,121,000	956,388,685
Cash And Bank Balances	321,067,061	603,552,814
	9,971,090,370	9,471,567,612
TOTAL ASSETS	18,877,513,719	18,439,450,481



588 - Q, Johar Town, Lahore - Pakisatn



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2026

	Three month ended		Nine Months Ended	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
	-----Rupees-----			
Sales- Net	3,084,746,120	3,341,107,922	10,787,560,091	10,100,185,059
Cost of Sales	(2,562,119,133)	(2,852,435,507)	(8,788,404,932)	(8,643,865,934)
Gross Profit	522,626,987	488,672,415	1,999,155,159	1,456,319,125
Administrative Expenses	54,105,916	57,257,879	165,952,038	161,904,092
Selling Expenses	60,554,025	35,876,526	178,443,759	119,703,970
	(114,659,941)	(93,134,405)	(344,395,797)	(281,608,062)
Operating Profit	407,967,047	395,538,010	1,654,759,363	1,174,711,063
Financial (Cost) /Income	(80,020,639)	(99,063,295)	(282,036,717)	(231,505,104)
	327,946,408	296,474,715	1,372,722,646	943,205,959
Other Income/(Loss)	22,551,828	23,173,268	79,345,127	165,818,206
	350,498,235	319,647,983	1,452,067,772	1,109,024,165
Other Expenses	(24,053,800)	(25,431,096)	(99,651,710)	(80,335,099)
Profit before income taxes and final tax	326,444,435	294,216,887	1,352,416,062	1,028,689,066
Taxation - Final taxes	-	-	-	(4,004)
Profit before income tax	326,444,435	294,216,887	1,352,416,062	1,028,685,062
Taxation - Income tax	(51,029,268)	(73,841,712)	(468,975,837)	(349,842,286)
Profit after income tax	275,415,168	220,375,175	883,440,226	678,842,776
Earnings per share (EPS)				
- Basic and Diluted	1.21	0.96	3.87	2.97



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan

Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392 | www.citipharma.com.pk



Citi Pharma Limited

**CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2026**

Note	Three month ended		Nine Months Ended	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
-----Rupees-----				
Profit for the period	275,415,168	220,375,175	883,440,226	678,842,776
Other comprehensive income for the period	-	-	-	-
Item that will not be reclassified subsequently to Profit or Loss				
Revaluation Surplus on Land		-	-	-
Total comprehensive income for the Period	275,415,168	220,375,175	883,440,226	678,842,776



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan

Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392 www.citipharma.com.pk



Citi Pharma Limited

**CITI PHARMA LIMITED
STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2026**

PARTICULARS	SHARE CAPITAL	SHARE DEPOSIT MONEY	CAPITAL RESERVES		REVENUE RESERVES	TOTAL
			REVALUATION SURPLUS	SHARE PREMIUM	UN-APPROPRIATED PROFIT	
----- Rupees -----						
Balance as at July 01, 2024	2,284,612,000	-	309,294,525	1,391,532,000	1,647,690,917	5,633,129,442
Total Comprehensive Income for the nine months						
Final Dividend Paid for the year ended June 2024 @ 32.5%	-	-	-	-	(742,498,900)	(742,498,900)
Profit for the period	-	-	-	-	678,842,776	678,842,776
Other comprehensive income	-	-	-	-	-	-
Balance as at March 31, 2025	2,284,612,000	-	309,294,525	1,391,532,000	1,584,034,793	5,569,473,318
Total Comprehensive Income for the nine months						
Balance as at July 01, 2025	2,284,612,000	-	5,384,617,300	1,391,532,000	1,806,817,381	10,867,578,681
Final Dividend Paid for the year ended June 2025 @ 35%	-	-	-	-	(799,614,200)	(799,614,200)
Profit for the period	-	-	-	-	883,440,226	883,440,226
Other comprehensive income	-	-	-	-	-	-
Balance as at March 31, 2026	2,284,612,000	-	5,384,617,300	1,391,532,000	1,890,643,407	10,951,404,707



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2026

March 31, 2026 March 31, 2025
-----Rupees-----

CASH FLOW FROM OPEARTING ACTIVITIES

Profit Before Taxation for the period	1,352,416,062	1,028,689,066
Adjustments For Non- Cash Items And Other Line Items:		
Depreciation	137,575,042	119,267,634
Financial Charges	282,036,717	231,505,104
Accrued Interest Income	-	(7,510,295)
Unrealized Gain/Loss on Investment in Shares	-	4,536,958
Amortization and Extinguishment of Deferred Grant	-	(582,494)
Worker's Profit Participation Fund	72,603,389	55,224,360
Worker's Welfare Fund	27,048,321	20,573,781
	519,263,469	423,015,049
Profit/ (Loss) before working capital changes	1,871,679,532	1,451,704,115

Effect of working capital changes

Advances, Deposits And Prepayments	(92,107,590)	52,129,049
Trade Debts	(1,139,271,260)	(1,341,546,778)
Stock In Trade	(476,857,469)	(895,721,955)
Trade And Other Payables	(286,773,649)	888,640,295
	(1,995,009,968)	(1,296,499,389)

Financial Charges Paid	(234,223,529)	(262,603,897)
Income Tax Paid	(542,628,334)	(426,353,670)
Gratuity Paid	-	-
Worker's Profit Participation Fund	(72,611,424)	(68,780,302)
	(849,463,286)	(757,737,870)
Net cash flow from operating activities	(972,793,723)	(602,533,144)

CASH FLOW FROM INVESTING ACTIVITIES

Purchase Of Property, Plant & Equipment	(49,975,885)	(45,519,385)
Paid for Capital Work in Progress	(23,789,638)	(127,563,025)
Paid for Long Term Security Deposits	(2,350,000)	(8,768,141)
Short Term Investments	63,378,575	19,815,262
Net cash flow from investing activities	(12,736,948)	(162,035,289)

CASH FLOW FROM FINANCING ACTIVITIES

Long-term loans obtained/ (repaid)	77,429,000	(12,859,000)
Due to Related Parties	(5,686,383)	(40,148,000)
Lease Rentals Paid	(11,987,647)	(8,727,657)
Dividend Paid	(801,177,914)	(741,386,647)
Short Term Borrowings	556,548,432	1,516,732,035
Net Cash flow From Investing Activities	(184,874,512)	713,610,732

Net Increase/ (decrease) in cash and cash equivalents

	(1,170,405,183)	(50,957,701)
Cash and cash equivalents at beginning of the period	1,491,472,244	1,278,333,631
Cash and cash equivalents at end of the period	321,067,061	1,227,375,930

Cash and cash equivalents compromise of:

Cash in hand	9,757,564	2,601,846
Cash at banks	311,309,497	28,119,815
Short Term Investments	-	1,196,654,269
	321,067,061	1,227,375,930



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk